News

sulfasalazin penicillin sulfasalazin och alkohol sulfasalazin forum
Hilleman Labs achieves successful outcome of Phase I/II Clinical Trial of its Oral Cholera Vaccine Hillchol
Date: 12/10/2017

Delivering on its mission to develop affordable vaccines for global health, Hilleman Laboratories today announced that it has successfully completed the Phase I/II Clinical Trials of its novel Oral Cholera Vaccine HillcholTM to address growing need to stop Cholera in the developing world.

Hilleman Labs successfully completes Phase I/II Clinical Trial of its Heat Stable Rotavirus Vaccine (HSRV)
Date: 12/10/2017

Making headway towards providing the developing nations an affordable and easy-to-use Heat Stable Rotavirus Vaccine (HSRV), Hilleman Laboratories, a joint-venture between Merck Sharp & Dohme (MSD) and the Wellcome Trust, today announced the successful completion of Phase I/II clinical trial of its oral vaccine against the deadly Rotavirus disease.

Hilleman Laboratories receives Indo-Swedish grant for developing - Oral Cholera Vaccine (OCV)
Date: 28/09/2017

Hilleman Laboratories, a joint-venture partnership between MSD and Wellcome Trust, received a 6 million krona Indo – Swedish grant for the project ‘Improved, affordable single strain whole cell-B subunit oral cholera vaccine’.

Building Healthy Partnership
Date: 04/05/2017

Though India has scored several successes such as eradication of polio and reduction in the rates of infant and maternal mortality, there’s a long road ahead

zyprexa 60 mg markenavnsmerte.site zyprexa the oa
atomoxetin fass atomoxetin lilly atomoxetin hydrochlorid
Hilleman Laboratories signs MoU with NICED, ICMR to develop Shigella Vaccine
Date: 29/03/2017

March 29th, 2017, New Delhi: Hilleman Laboratories, a joint-venture partnership between MSD and Wellcome Trust, today, signed a Memorandum of Understanding (MoU) with National Institute of Cholera and Enteric Diseases (NICED), an ICMR organization for further development and commercialization of the Shigella vaccines and other enteric vaccines for diarrheal diseases. This agreement was signed as an effort of Hilleman’s mission to make affordable vaccines for the developing world population.

sulfasalazin penicillin sulfasalazin en 500 mg sulfasalazin forum
Hilleman Laboratories awarded global patents for Oral Cholera Vaccine
Date: 10/01/2017

New Delhi, 10 January, 2017: Hilleman Laboratories, a joint-venture partnership between MSD and Wellcome Trust, has announced that it has been awarded a set of global patents for its Oral Cholera Vaccine (OCV).

Nitya Sharma at Hilleman Labs and Amity University awarded the prestigious Prime Minister’s Fellowship
Date: 22/12/2016

Hilleman Labs partners with Amity University for the Prime Minister’s Fellowship Scheme for Doctoral Research. Nitya Sharma, a PhD (Immunology) scholar at Amity University is working on the development of immunodiagnostic assays for meningococcal antigens at Hilleman Labs

Sustained funding is difficult to get in India
Date: 11/10/2016

Corporate India hasn’t developed a high appetite for risk, in terms of accepting new technology. India is still evolving. Most companies like to go for tried-and-tested methods, rather than innovation

Hilleman Lab scouts for partners to launch rotavirus vaccine in India
Date: 28/09/2016

New Delhi: Hilleman Laboratories, an initiative between pharmaceutical giant Merck & Co (MSD Pharmaceuticals in India) and UK-based charitable organization Wellcome Trust, is in talks to partner domestic and global vaccine companies to manufacture and market its thermostable, or heat-resistant, rotavirus vaccine in India.

Hilleman Labs workshop on Nutrition and Immunity for Infant and Child Health
Date: 21/09/2016

New Delhi:Hilleman Laboratories, dedicated for improvement of child health by developing affordable vaccine for the developing world also understands and recognizes the importance of interplaying role of nutrition and immunity as the key factors along with vaccination in reducing childhood mortality and improving child health and development.